- Home
- RERE vs NUVB Comparison
RERE vs NUVB Comparison
Compare RERE & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- NUVB
- Stock Information
- Founded
- RERE 2011
- NUVB 2018
- Country
- RERE China
- NUVB United States
- Employees
- RERE N/A
- NUVB N/A
- Industry
- RERE Other Specialty Stores
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- NUVB Health Care
- Exchange
- RERE Nasdaq
- NUVB Nasdaq
- Market Cap
- RERE 757.2M
- NUVB 837.0M
- IPO Year
- RERE 2021
- NUVB N/A
- Fundamental
- Price
- RERE $4.53
- NUVB $2.91
- Analyst Decision
- RERE
- NUVB Strong Buy
- Analyst Count
- RERE 0
- NUVB 6
- Target Price
- RERE N/A
- NUVB $8.00
- AVG Volume (30 Days)
- RERE 3.4M
- NUVB 4.7M
- Earning Date
- RERE 08-20-2025
- NUVB 08-07-2025
- Dividend Yield
- RERE N/A
- NUVB N/A
- EPS Growth
- RERE N/A
- NUVB N/A
- EPS
- RERE 0.12
- NUVB N/A
- Revenue
- RERE $2,588,775,650.00
- NUVB $14,355,000.00
- Revenue This Year
- RERE $30.66
- NUVB $332.80
- Revenue Next Year
- RERE $25.12
- NUVB $360.12
- P/E Ratio
- RERE $38.16
- NUVB N/A
- Revenue Growth
- RERE 27.39
- NUVB 900.35
- 52 Week Low
- RERE $2.00
- NUVB $1.54
- 52 Week High
- RERE $4.93
- NUVB $3.46
- Technical
- Relative Strength Index (RSI)
- RERE 66.24
- NUVB 66.89
- Support Level
- RERE $4.23
- NUVB $2.57
- Resistance Level
- RERE $4.93
- NUVB $2.55
- Average True Range (ATR)
- RERE 0.33
- NUVB 0.20
- MACD
- RERE 0.08
- NUVB 0.03
- Stochastic Oscillator
- RERE 74.52
- NUVB 90.62
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.